Methods for regulating gastrointestinal motility
View Patent ↗Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
1. A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of an exendin effective for reducing gastric motility.
2. A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of an exendin effective for delaying gastric emptying.
3. The method according to claim 1 or 2 wherein said exendin is exendin-3.
4. The method according to claim 1 or 2 wherein said exendin is exendin-4.
5. The method according to claim 1 or 2 wherein said subject is undergoing a gastrointestinal diagnostic procedure.
6. The method according to claim 5 wherein said gastrointestinal diagnostic procedure is a radiological examination.
7. The method according to claim 6 wherein said gastric gastrointestinal diagnostic procedure is magnetic resonance imaging.
8. The method according to claim 1 or 2 wherein said subject is suffering from a gastrointestinal disorder.
9. A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of an exendin analog effective for reducing gastric motility, wherein said exendin analog is selected from a peptide compound of the formula:
1 5 10
Xaa 1 Xaa 2 Xaa 3 Gly Thr Xaa 4 Xaa 5 , Xaa 6 Xaa 7 Xaa 8
15 20
Ser Lys Gln Xaa 9 Glu Glu Glu Ala Val Arg Leu
25 30
Xaa 10 Xaa 11 Xaa 12 Xaa 13 Leu Lys Asn Gly Gly Xaa 14
35
Ser Ser Gly Ala Xaa 15 Xaa 16 Xaa 17 Xaa 18 -Z
wherein:
Xaa 1 is His, Arg or Tyr;
Xaa 2 is Ser, Gly, Ala or Thr;
Xaa 3 is Asp or Glu;
Xaa 4 is Phe, Tyr or naphthylalanine;
Xaa 5 is Thr or Ser;
Xaa 6 is Ser or Thr;
Xaa 7 is Asp or Glu;
Xaa 8 is Leu, Ile, Val, pentylglycine or Met;
Xaa 9 is Leu, Ile, pentylglycine, Val or Met;
Xaa 10 is Phe, Tyr or naphthylalanine;
Xaa 11 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;
Xaa 12 is Glu or Asp;
Xaa 13 is Trp, Phe, Tyr, or naphthylalanine;
Xaa 14 , Xaa 15 , Xaa 16 and Xaa 17 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine;
Xaa 18 is Ser, Thr or Tyr; and
Z is —OH or —NH 2 ;
with the proviso that the compound does not have the formula of either exendin-3 or exendin-4 and pharmaceutically acceptable salts thereof.
10. A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of an exendin analog effective for reducing gastric motility, wherein said exendin analog is selected from a peptide compound of the formula:
1 5 10
Xaa 1 Xaa 2 Xaa 3 Gly Thr Xaa 4 Xaa 5 , Xaa 6 Xaa 7 Xaa 8
15 20
Ser Lys Gln Xaa 9 Glu Glu Glu Ala Val Arg Leu
25 30
Xaa 10 Xaa 11 Xaa 12 Xaa 13 Leu Lys Asn Gly Gly Xaa 14
35
Ser Ser Gly Ala Xaa 15 Xaa 16 Xaa 17 Xaa 18 -Z
wherein:
Xaa 1 is His or Arg;
Xaa 2 is Ser or Gly;
Xaa 3 is Asp or Glu;
Xaa 4 is Phe or naphthylalanine;
Xaa 5 is Thr or Ser;
Xaa 6 is Ser or Thr;
Xaa 7 is Asp or Glu;
Xaa 8 is Leu or pentylglycine
Xaa 9 is Leu or pentylglycine;
Xaa 10 is Phe or naphthylalanine;
Xaa 11 is Ile, Val or tert-butylglycine;
Xaa 12 is Glu or Asp;
Xaa 13 is Trp or Phe;
Xaa 14 , Xaa 15 , Xaa 16 and Xaa 17 are independently selected from Pro, homoproline or N-methylalanine;
Xaa 18 is Ser or Tyr; and
Z is —OH or —NH 2 ;
with the proviso that the compound does not have the formula of either exendin-3 or exendin-4 and pharmaceutically acceptable salts thereof.
11. A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of an exendin analog effective for delaying gastric emptying, wherein said exendin analog is selected from a peptide compound of the formula:
1 5 10
Xaa 1 Xaa 2 Xaa 3 Gly Thr Xaa 4 Xaa 5 , Xaa 6 Xaa 7 Xaa 8
15 20
Ser Lys Gln Xaa 9 Glu Glu Glu Ala Val Arg Leu
25 30
Xaa 10 Xaa 11 Xaa 12 Xaa 13 Leu Lys Asn Gly Gly Xaa 14
35
Ser Ser Gly Ala Xaa 15 Xaa 16 Xaa 17 Xaa 18 -Z
wherein:
Xaa 1 is His, Arg or Tyr;
Xaa 2 is Ser, Gly, Ala or Thr;
Xaa 3 is Asp or Glu;
Xaa 4 is Phe, Tyr or naphthylalanine;
Xaa 5 is Thr or Ser;
Xaa 6 is Ser or Thr;
Xaa 7 is Asp or Glu;
Xaa 8 is Leu, Ile, Val, pentylglycine or Met;
Xaa 9 is Leu, Ile, pentylglycine, Val or Met;
Xaa 10 is Phe, Tyr or naphthylalanine;
Xaa 11 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;
Xaa 12 is Glu or Asp;
Xaa 13 is Trp, Phe, Tyr, or naphthylalanine;
Xaa 14 , Xaa 15 , Xaa 16 and Xaa 17 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine;
Xaa 18 is Ser, Thr or Tyr; and
Z is —OH or —NH 2 ;
with the proviso that the compound does not have the formula of either exendin-3 or exendin-4 and pharmaceutically acceptable salts thereof.
12. A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of an exendin analog effective for delaying gastric emptying, wherein said exendin analog is selected from a peptide compound of the formula:
1 5 10
Xaa 1 Xaa 2 Xaa 3 Gly Thr Xaa 4 Xaa 5 , Xaa 6 Xaa 7 Xaa 8
15 20
Ser Lys Gln Xaa 9 Glu Glu Glu Ala Val Arg Leu
25 30
Xaa 10 Xaa 11 Xaa 12 Xaa 13 Leu Lys Asn Gly Gly Xaa 14
35
Ser Ser Gly Ala Xaa 15 Xaa 16 Xaa 17 Xaa 18 -Z
wherein:
Xaa 1 is His or Arg;
Xaa 2 is Ser or Gly;
Xaa 3 is Asp or Glu;
Xaa 4 is Phe or naphthylalanine;
Xaa 5 is Thr or Ser;
Xaa 6 is Ser or Thr;
Xaa 7 is Asp or Glu;
Xaa 8 is Leu or pentylglycine
Xaa 9 is Leu or pentylglycine;
Xaa 10 is Phe or naphthylalanine;
Xaa 11 is Ile, Val or tert-butylglycine;
Xaa 12 is Glu or Asp;
Xaa 13 is Trp or Phe;
Xaa 14 , Xaa 15 , Xaa 16 and Xaa 17 are independently selected from Pro, homoproline or N-methylalanine;
Xaa 18 is Ser or Tyr; and
Z is —OH or —NH 2 ;
with the proviso that the compound does not have the formula of either exendin-3 or exendin-4 and pharmaceutically acceptable salts thereof.
13. The method according to claim 9 , 10 , 11 , or 12 wherein said subject is undergoing a gastrointestinal diagnostic procedure.
14. The method according to claim 13 wherein said gastrointestinal diagnostic procedure is a radiological examination.
15. The method according to claim 14 wherein said gastric gastrointestinal diagnostic procedure is magnetic resonance imaging.
16. The method according to claim 9 , 10 , 11 , or 12 wherein said subject is suffering from a gastrointestinal disorder.
17. A method of reducing gastric motility in a subject in need thereof comprising administering to said subject an amount of exendin-4 effective for reducing gastric motility.
18. A method of delaying gastric emptying in a subject in need thereof comprising administering to said subject an amount of exendin-4 effective for delaying gastric emptying.
19. The method according to claim 17 or 18 wherein said subject is undergoing a gastrointestinal diagnostic procedure.
20. The method according to claim 19 wherein said gastrointestinal diagnostic procedure is a radiological examination.
21. The method according to claim 20 wherein said gastric gastrointestinal diagnostic procedure is magnetic resonance imaging.
22. The method according to claim 17 or 18 wherein said subject is suffering from a gastrointestinal disorder.